A Randomized Controlled Trial Investigating the Survival Benefit of Dose-Intensified Multidrug Combination Chemotherapy (LSG9) for Intermediate- or High-Grade Non-Hodgkin's Lymphoma : Japan Clinical Oncology Group Study 9002

• KINOSHITA Tomohiro

  Nagoya University Graduate School of Medicine

• HOTTA Tomomitsu

  Tokai University

• TOBINAI Kensei

  National Cancer Center Hospital

• KOBAYASHI Tohru

  Mie University School of Medicine

• ISHIZUKA Naoki

  National Cancer Center Research Institute

• TOMONAGA Masao

  Nagasaki University

• SAI Toshiaki

  Iwaki Kyoritsu General Hospital

• OHNO Youichiro

  Tenri Hospital, Tenri

• KASAI Masaharu

  Sapporo Hokuyu Hospital

• OGURA Michinori

  Aichi Cancer Center

• MIKUNI Chikara

  Sapporo National Hospital

• TOKI Hironobu

  National Shikoku Cancer Center

• SANO Masayuki

  Saga Medical School

• MASAKI Yasufumi

  Kanazawa Medical University

• OHTSU Tomoko

  National Cancer Center Hospital

• MATSUNO Yoshihiro

  National Cancer Center Hospital

• TAKENAKA Takeaki

  National Cancer Center Hospital

• SHIRAKAWA Shigeru

  Mie University School of Medicine

• SHIMOYAMA Masanori

  National Cancer Center Hospital

収録刊行物

• International journal of hematology

  International journal of hematology 80 (4), 341-350, 2004-11-15

キーワード

• Non-Hodgkin's lymphoma
• Combination chemotherapy
• Dose intensity
• Doxorubicin
• Randomized controlled trial

詳細情報

• CRID: 1573105974737701888
• NII論文ID: 10014022970
• NII書誌ID: AA10797094
• ISSN: 09255710
• Web Site: https://search.jamas.or.jp/link/ui/2006149495
• 本文言語コード: en
• データソース種別:
  • CiNii Articles